Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071727216> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2071727216 endingPage "19" @default.
- W2071727216 startingPage "18" @default.
- W2071727216 abstract "Overexpression of the epidermal growth factor receptor (EGFR) is a common characteristic of head and neck squamous cell carcinomas (HNSCC). Cetuximab is a chimeric anti-EGFR monoclonal antibody (mAb) with multiple approved indications in HNSCC, including with radiation therapy (RT) for locoregionally advanced disease, as monotherapy after platinum progression, and with platinum/5-fluorouracil for recurrent or metastatic disease. There remain, however, numerous unanswered questions regarding the optimal use of cetuximab in HNSCC, including patient selection, its mechanisms of action and resistance, the effect of human papillomavirus status on outcomes, its role when combined with induction chemotherapy or adjuvant radiation, and optimal management of skin toxicity and hypersensitivity reactions. In addition, a variety of other anti-EGFR agents (the multitargeted small molecule tyrosine kinase inhibitors [TKIs] lapatinib, dacomitinib, and afatinib and the anti-EGFR mAbs zalutumumab, nimotuzumab, and panitumumab) are currently under investigation in phase II and III clinical trials in different HNSCC therapeutic settings. The anti-EGFR TKI erlotinib is currently in phase III development for oral cancer prevention. Numerous other drugs are in earlier stages of development for HNSCC treatment, including novel anti-EGFR mAbs (MEHD7945A, necitumumab, and RO5083945), small-molecule TKIs (vandetanib, icotinib, and CUDC-101), EGFR antisense, various add-on therapies to radiation and chemotherapy (bevacizumab, interleukin-12, lenalidomide, alisertib, and VTX-2337), and drugs (temsirolimus, everolimus, OSI-906, dasatinib, and PX-866) intended to overcome resistance to anti-EGFR agents. Overall, a wealth of clinical trial data is expected in the coming years, with the potential to modify significantly the approach to anti-EGFR therapy for HNSCC." @default.
- W2071727216 created "2016-06-24" @default.
- W2071727216 creator A5009826873 @default.
- W2071727216 creator A5024980917 @default.
- W2071727216 creator A5028173210 @default.
- W2071727216 creator A5045415451 @default.
- W2071727216 creator A5046795494 @default.
- W2071727216 creator A5057032257 @default.
- W2071727216 creator A5068014441 @default.
- W2071727216 creator A5075804584 @default.
- W2071727216 creator A5079574915 @default.
- W2071727216 creator A5083494199 @default.
- W2071727216 date "2010-11-01" @default.
- W2071727216 modified "2023-09-26" @default.
- W2071727216 title "27A Targeting the PI3K/mTOR pathway in genetically engineered mouse models of advanced prostate cancer" @default.
- W2071727216 doi "https://doi.org/10.1016/s1359-6349(10)71731-6" @default.
- W2071727216 hasPublicationYear "2010" @default.
- W2071727216 type Work @default.
- W2071727216 sameAs 2071727216 @default.
- W2071727216 citedByCount "0" @default.
- W2071727216 crossrefType "journal-article" @default.
- W2071727216 hasAuthorship W2071727216A5009826873 @default.
- W2071727216 hasAuthorship W2071727216A5024980917 @default.
- W2071727216 hasAuthorship W2071727216A5028173210 @default.
- W2071727216 hasAuthorship W2071727216A5045415451 @default.
- W2071727216 hasAuthorship W2071727216A5046795494 @default.
- W2071727216 hasAuthorship W2071727216A5057032257 @default.
- W2071727216 hasAuthorship W2071727216A5068014441 @default.
- W2071727216 hasAuthorship W2071727216A5075804584 @default.
- W2071727216 hasAuthorship W2071727216A5079574915 @default.
- W2071727216 hasAuthorship W2071727216A5083494199 @default.
- W2071727216 hasConcept C121608353 @default.
- W2071727216 hasConcept C126322002 @default.
- W2071727216 hasConcept C143998085 @default.
- W2071727216 hasConcept C2776530083 @default.
- W2071727216 hasConcept C2776833033 @default.
- W2071727216 hasConcept C2777329042 @default.
- W2071727216 hasConcept C2777506169 @default.
- W2071727216 hasConcept C2778087573 @default.
- W2071727216 hasConcept C2778332735 @default.
- W2071727216 hasConcept C2779438470 @default.
- W2071727216 hasConcept C2779786085 @default.
- W2071727216 hasConcept C2779998722 @default.
- W2071727216 hasConcept C2780586478 @default.
- W2071727216 hasConcept C502942594 @default.
- W2071727216 hasConcept C526805850 @default.
- W2071727216 hasConcept C530470458 @default.
- W2071727216 hasConcept C71924100 @default.
- W2071727216 hasConcept C98274493 @default.
- W2071727216 hasConceptScore W2071727216C121608353 @default.
- W2071727216 hasConceptScore W2071727216C126322002 @default.
- W2071727216 hasConceptScore W2071727216C143998085 @default.
- W2071727216 hasConceptScore W2071727216C2776530083 @default.
- W2071727216 hasConceptScore W2071727216C2776833033 @default.
- W2071727216 hasConceptScore W2071727216C2777329042 @default.
- W2071727216 hasConceptScore W2071727216C2777506169 @default.
- W2071727216 hasConceptScore W2071727216C2778087573 @default.
- W2071727216 hasConceptScore W2071727216C2778332735 @default.
- W2071727216 hasConceptScore W2071727216C2779438470 @default.
- W2071727216 hasConceptScore W2071727216C2779786085 @default.
- W2071727216 hasConceptScore W2071727216C2779998722 @default.
- W2071727216 hasConceptScore W2071727216C2780586478 @default.
- W2071727216 hasConceptScore W2071727216C502942594 @default.
- W2071727216 hasConceptScore W2071727216C526805850 @default.
- W2071727216 hasConceptScore W2071727216C530470458 @default.
- W2071727216 hasConceptScore W2071727216C71924100 @default.
- W2071727216 hasConceptScore W2071727216C98274493 @default.
- W2071727216 hasIssue "7" @default.
- W2071727216 hasLocation W20717272161 @default.
- W2071727216 hasOpenAccess W2071727216 @default.
- W2071727216 hasPrimaryLocation W20717272161 @default.
- W2071727216 hasRelatedWork W1975540192 @default.
- W2071727216 hasRelatedWork W1980211974 @default.
- W2071727216 hasRelatedWork W2023373067 @default.
- W2071727216 hasRelatedWork W2025029856 @default.
- W2071727216 hasRelatedWork W2028009636 @default.
- W2071727216 hasRelatedWork W2062707457 @default.
- W2071727216 hasRelatedWork W2101542880 @default.
- W2071727216 hasRelatedWork W2297422279 @default.
- W2071727216 hasRelatedWork W2332684061 @default.
- W2071727216 hasRelatedWork W4294612547 @default.
- W2071727216 hasVolume "8" @default.
- W2071727216 isParatext "false" @default.
- W2071727216 isRetracted "false" @default.
- W2071727216 magId "2071727216" @default.
- W2071727216 workType "article" @default.